Frankfurt
21.10.26 | 15:25
22,400 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 22,600 | 23,400 | 07:56 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Nanobiotix S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 01.10. | Nanobiotix names new CFO | 9 | Seeking Alpha | ||
| 01.10. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| NANOBIOTIX SA ADR Aktie jetzt für 0€ handeln | |||||
| 01.10. | Nanobiotix S.A.: NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer | 253 | GlobeNewswire (Europe) | PARIS and CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the "Company"), a late-stage clinical biotechnology company pioneering physics-based approaches... ► Artikel lesen | |
| 28.09. | Can J&J's Partnership Drive More Upside for Nanobiotix? | 11 | Insider Monkey | ||
| 24.09. | Nanobiotix GAAP EPS of -€0.70, revenue of €5.6M | 3 | Seeking Alpha | ||
| 24.09. | Nanobiotix S.A.: NANOBIOTIX Provides First Half 2026 Operational and Financial Update | 547 | GlobeNewswire (Europe) | Promising early results reported from full cohort analysis of the completed dose-escalation and expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with inoperable, locoregionally... ► Artikel lesen | |
| 22.09. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 2 | GlobeNewswire (USA) | ||
| 22.09. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 15.09. | Guggenheim initiates Nanobiotix stock rating at Buy on cancer drug | 5 | Investing.com | ||
| 14.09. | Nanobiotix S.A.: NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer | 482 | GlobeNewswire (Europe) | All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was... ► Artikel lesen | |
| 09.09. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 25.08. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 2 | GlobeNewswire (USA) | ||
| 25.08. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 31.07. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 9 | SEC Filings | ||
| 30.07. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 2 | GlobeNewswire (USA) | ||
| 08.06. | Nanobiotix S.A. - S-8, Securities to be offered to employees in employee benefit plans | 5 | SEC Filings | ||
| 05.06. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 6 | GlobeNewswire (USA) | ||
| 05.06. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 04.06. | Leerink raises Nanobiotix stock price target on cancer drug data | 13 | Investing.com |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 5,550 | 0,00 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 5,360 | -0,92 % | Cosciens Biopharma Inc (2): Cosciens raises $12M of up to $20M debenture deal | ||
| HALOZYME THERAPEUTICS | 111,95 | +0,72 % | H.C. Wainwright reiterates Halozyme stock rating on Takeda trial data | ||
| ABCELLERA BIOLOGICS | 10,620 | -2,57 % | AbCellera-Aktie mit +450% - nächstes Ziel 20 US$? | Die AbCellera-Aktie hat innerhalb weniger Monate eine beeindruckende Rallye hingelegt. Vom Frühjahrstief bei rund 3,00 US$ stieg der Kurs zeitweise bis auf 15,00 US$. Nach diesem Anstieg läuft nun eine... ► Artikel lesen | |
| GLOW LIFETECH | 0,015 | 0,00 % | Smallcap Discoveries: Glow Lifetech Corp. to Present at the Annual Smallcap Discoveries Conference in Vancouver | Toronto, Ontario--(Newsfile Corp. - September 24, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce that it will be participating in... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 321,40 | 0,00 % | ROUNDUP/'WSJ': US-Investor Elliot steigt bei Sartorius-Großaktionär Bio-Rad ein | NEW YORK (dpa-AFX) - Der US-Investor Elliott hat laut einem Medienbericht eine beachtliche Beteiligung an dem Sartorius-Großaktionär Bio-Rad Laboratories aufgebaut. Der aktivistische Investor wolle... ► Artikel lesen | |
| AVID BIOSERVICES | - | - | Avid Bioservices Appoints Maria Ebro Andreasen as Chief People Officer to Fuel Continued Growth and Talent Strategy | Company expands team, university partnerships, and internship programs to build long-term biologics talent pipeline.TUSTIN, Calif., May 18, 2026 /PRNewswire/ -- Avid Bioservices, a leading... ► Artikel lesen | |
| BIOLINERX | 1,730 | +2,37 % | BioLineRx Ltd.: BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update | - Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third patient cohort expected to commence dosing in September -
- Announced new data... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 2,112 | -2,94 % | Minerva Neurosciences, Inc: Minerva Neurosciences to Participate in Two Upcoming Investor Conferences | BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 2,640 | 0,00 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights | Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026
Cash, cash equivalents and short-term... ► Artikel lesen | |
| INNOVENT BIOLOGICS | 10,006 | 0,00 % | CMBI Raises INNOVENT BIO TP to HKD138.63, IBI3003 Clinical Data Validate Leadership in MM TCE Field | ||
| OVID THERAPEUTICS | 2,080 | 0,00 % | Ovid Therapeutics Inc.: Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results | First-ever oral direct KCC2 activator, OV4071, advancing in an ongoing Phase 1 studyInitiated Phase 2 proof-of-concept and photosensitivity studies for OV329, a next-generation GABA-AT inhibitorA... ► Artikel lesen | |
| GEOVAX LABS | 0,232 | 0,00 % | EQS-News: GeoVax, Inc.: GeoVax to Highlight Next-Generation MVA Vaccine and Manufacturing Advances at World Vaccine Congress Europe 2026 | EQS-News: GeoVax, Inc.
/ Key word(s): Science
GeoVax to Highlight Next-Generation MVA Vaccine and Manufacturing Advances at World Vaccine Congress Europe 2026 06.10.2026 / 14:37... ► Artikel lesen | |
| COCRYSTAL | 0,815 | 0,00 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors | BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet... ► Artikel lesen |
NANOBIOTIX SA ADR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 22,400 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOBIOTIX SA ADR finden Sie auf Wallstreet Online.